St Jude Medical Inc (NYSE:STJ) has received US approval of BurstDR stimulation, a treatment for people with chronic spinal chord (SCS) pain.
The St Paul-based company said BurstDR stimulation had been clinically proven to improve upon traditional SCS therapy by generating superior pain relief.
BurstDR uses intermittent “burst” pulses designed to mimic the body’s natural nerve impulse patterns.
St Jude introduced it after nearly a decade of research and study in collaboration with Prof. Dirk De Ridder, who filed the therapy’s initial patents in 2004.
Chronic pain affects approximately 1.5bn people worldwide, more than heart disease, cancer and diabetes combined.
“Chronic pain is one of the most costly epidemic diseases facing health care systems worldwide, and one of the most challenging for physicians to manage due to the complexity of the condition and the differences in each patient’s clinical case,” said Allen Burton, medical director of neuromodulation and vice president of medical affairs.
“With FDA approval of BurstDR stimulation, we are empowering physicians with a new therapy option in their fight against widespread chronic pain.”
St Jude shares edged higher to US$80.18.
Story by ProactiveInvestors